A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Clinical trial NCT07213882 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07213882
Sponsor: Assistance Publique - Hôpitaux de Paris
Status: NOT_YET_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Cutaneous T Cell Lymphoma (CTCL)Mycosis Fungoides Sezary Syndrome

Start date: 2026-01-01
Primary completion: 2028-08-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.